{
    "Clinical Trial ID": "NCT03098550",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Nivolumab + Daratumumab (TNBC)",
        "  Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "INTERVENTION 2: ",
        "  Nivolumab + Daratumumab (NSCLC)",
        "  Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com",
        "  Patients with metastatic or advanced solid tumors",
        "  Women with histologically or cytologically confirmed triple negative breast carcinoma",
        "  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma",
        "  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)",
        "Exclusion Criteria:",
        "  Active brain metastases or leptomeningeal metastases.",
        "  Any serious or uncontrolled medical disorder",
        "  Prior malignancy active within the previous 3 years",
        "  Other protocol defined inclusion/exclusion criteria could apply"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With Adverse Events (AEs)",
        "  Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab",
        "  Time frame: From first dose to 30 days post last dose (up to 34 months)",
        "Results 1: ",
        "  Arm/Group Title: Nivolumab + Daratumumab (TNBC)",
        "  Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "  Overall Number of Participants Analyzed: 41",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  41 100.0%",
        "Results 2: ",
        "  Arm/Group Title: Nivolumab + Daratumumab (NSCLC)",
        "  Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)",
        "  Overall Number of Participants Analyzed: 21",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  21 100.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 36/41 (87.80%)",
        "  Anaemia 0/41 (0.00%)",
        "  Febrile bone marrow aplasia 1/41 (2.44%)",
        "  Acute coronary syndrome 0/41 (0.00%)",
        "  Atrial fibrillation 0/41 (0.00%)",
        "  Cardiac tamponade 1/41 (2.44%)",
        "  Cardio-respiratory arrest 0/41 (0.00%)",
        "  Pericardial effusion 0/41 (0.00%)",
        "  Abdominal pain 0/41 (0.00%)",
        "  Colitis 0/41 (0.00%)",
        "  Diarrhoea 0/41 (0.00%)",
        "Adverse Events 2:",
        "  Total: 17/21 (80.95%)",
        "  Anaemia 0/21 (0.00%)",
        "  Febrile bone marrow aplasia 0/21 (0.00%)",
        "  Acute coronary syndrome 1/21 (4.76%)",
        "  Atrial fibrillation 0/21 (0.00%)",
        "  Cardiac tamponade 0/21 (0.00%)",
        "  Cardio-respiratory arrest 0/21 (0.00%)",
        "  Pericardial effusion 1/21 (4.76%)",
        "  Abdominal pain 0/21 (0.00%)",
        "  Colitis 1/21 (4.76%)",
        "  Diarrhoea 1/21 (4.76%)"
    ]
}